PROTEOMICS AT YOUR
FINGERSTIPS
Starting with ProteoMix™ RUO kits as our first commercial product, we will expand into point-of-care and true at-home systems — ushering in the era of distributed and telehealth diagnostics.
ONE SCALABLE PLATFORM.
TWO MASSIVE MARKETS.
Research proteomics and clinical immunoassay diagnostics represent a >$200B long-term market, with an addressable opportunity of ~$60B — powered by ProteoNex™ chemistry.
FIRST PRODUCT:
PROTEOMIX™
MULTIPLEX KITS
We deliver multiplex proteomics through reagent kits that run on >300,000 installed qPCR instruments — no new hardware required.
Leverages
Existing
Infrastructure
No Additional
Hardware
Needed
Efficient and
Cost-Effective
Built for
Scalable
Roadmap
PROTEONEX™
TECHNOLOGY
eGlint’s ProteoNex™ platform uses aptamer-based biosensors on high-density microarrays to measure combinations of virtually any protein biomarkers.
General and
Quantitative
Quantifies virtually any biomarker from a blood sample
Highly
Multiplexed
Performs hundreds of assays at once
Simple and
Rapid
Delivers results within minutes without sample purification
Affordable and
Scalable
Lowers cost per sample and dramatically lowers cost per biomarker
PROTEOMICS TODAY IS TOO SLOW, TOO HARD, AND TOO LIMITED.
WE FIX THAT.
ProteoNex™ is a 10-minute, multiplex, one-step assay —
at a fraction of ELISA's cost
LEADERSHIP TEAM
eGlint is led by repeat operators with $3.7B in combined exits
and multiple Dx products launched.
Executive Team
$4M RAISED TO DATE
Building toward commercialization of our first ProteoMix™ product
Investors may request a non-confidential overview at investor@eglintbio.com
VALIDATED BY INDUSTRY STRATEGICS
Our platform has been technically and strategically vetted by major industry players.
✔
Pilot completed and partnership established with a leading life science tools company, confirming compatibility of our platform and robust assay performance.
✔
Technical and strategic validation by a major industry player following deep diligence.
✔
Ongoing collaboration with a large IVD company measuring cytokines in clinical samples.
✔
Named a “Cool Company 2025” by Connect San Diego.
